Skip to main content

Ten-year outcomes for prostate cancer patients with Gleason 8 through 10 treated with external beam radiation and high-dose-rate brachytherapy boost in the PSA era

Journal of Radiation Oncology volume 5, pages 87–93 (2016)Cite this article

Abstract

Objective

High-dose-rate (HDR) brachytherapy boost represents a method to dose escalate in high-risk prostate cancer; the purpose of this analysis is to report long-term outcomes for a group of high-risk patients with Gleason 8 through 10 prostate cancer treated with HDR brachytherapy boost from a multi-national cohort study.

Methods

Between 1987 and 2002, 483 patients with Gleason 8–10 prostate cancer were treated on four prospective trials of HDR boost. Conformal external beam radiotherapy (EBRT) was delivered to the pelvis (dose range 36–50.4 Gy) along with HDR boost for a combined biologic equivalent dose (BED) of 215–366 Gy (α/β = 1.2) and cumulative dose of 64–72 Gy.

Results

Mean/median follow-up was 6.1/5.1 years. The 10-year rates of biochemical control (BC), distant metastases (DM), clinical failure (CF), cause-specific survival (CSS), and overall survival (OS) were 53.5, 22.1, 25.6, 82.6, and 62.7 %, respectively. Androgen deprivation was given in 69.9 % of patients (predominantly short course) but did not significantly improve BC, DM, CSS, or OS. When stratified by initial PSA (iPSA), 10-year outcomes were improved with lower iPSA (<40) including BC (57.4 vs. 10.3 %, p < 0.001); freedom from distant metastases (81.5 vs. 43.4 %, p < 0.001); CSS (85.0 vs. 59.1 %, p < 0.001); and OS (63.8 vs. 47.9 %, p = 0.02).

Conclusion

A combination of HDR brachytherapy boost and EBRT provides a high BED with high rates of disease control and excellent disease specific survival for patients with Gleason 8 through 10 prostate cancer even with iPSA up to 40 ng/ml. Hormonal therapy did not improve outcomes in this cohort of patients when the radiation dose was escalated with an HDR prostate boost.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Zelefsky MJ, Yamada Y, Fuks Z et al (2008) Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 71:1028–1033

    Article  PubMed  Google Scholar 

  2. Kuban DA, Tucker SL, Dong L et al (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67–74

    Article  PubMed  Google Scholar 

  3. Martinez A, Gonzalez J, Spencer W et al (2003) Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol 169:974–979

    Article  PubMed  Google Scholar 

  4. Demanes DJ, Rodriguez RR, Schour L et al (2005) High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy’s 10-year results. Int J Radiat Oncol Biol Phys 61:1306–1316

    Article  PubMed  Google Scholar 

  5. Galalae RM, Kovacs G, Schultze J et al (2002) Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 52:81–90

    Article  PubMed  Google Scholar 

  6. Martinez-Monge R, Moreno M, Ciervide R et al (2012) External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome. Int J Radiat Oncol Biol Phys 82:e469–e476

    Article  PubMed  Google Scholar 

  7. Hoskin PJ, Rojas AM, Brownes PJ et al (2012) Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 103:217–222

    Article  PubMed  Google Scholar 

  8. Martin T, Roddiger S, Kurek R et al (2004) 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer. Radiother Oncol 71:35–41

    Article  PubMed  Google Scholar 

  9. Edmundson GK, Yan D, Martinez AA (1995) Intraoperative optimization of needle placement and dwell times for conformal prostate brachytherapy. Int J Radiat Oncol Biol Phys 33:1257–1263

    Article  CAS  PubMed  Google Scholar 

  10. Edmundson GK, Rizzo NR, Teahan M et al (1993) Concurrent treatment planning for outpatient high dose rate prostate template implants. Int J Radiat Oncol Biol Phys 27:1215–1223

    Article  CAS  PubMed  Google Scholar 

  11. Grills IS, Martinez AA, Hollander M et al (2004) High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 171:1098–1104

    Article  PubMed  Google Scholar 

  12. Stewart SB, Boorjian SA (2014) Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective. Urol Oncol

  13. Abdollah F, Klett DE, Sood A et al (2014) Predicting pathologic outcomes in patients undergoing robotic-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram. BJU Int

  14. Do TM, Parker RG, Smith RB et al (2001) High-grade carcinoma of the prostate: a comparison of current local therapies. Urology 57:1121–1126

    Article  CAS  PubMed  Google Scholar 

  15. Manoharan M, Bird VG, Kim SS et al (2003) Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of >/=8. BJU Int 92:539–544

    Article  CAS  PubMed  Google Scholar 

  16. Boorjian SA, Karnes RJ, Rangel LJ et al (2008) Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8–10 cancers. BJU Int 101:299–304

    Article  PubMed  Google Scholar 

  17. Audenet F, Comperat E, Seringe E et al (2011) Oncologic control obtained after radical prostatectomy in men with a pathological Gleason score >/= 8: a single-center experience. Urol Oncol 29:602–607

    Article  PubMed  Google Scholar 

  18. Pahlajani N, Ruth KJ, Buyyonouski MK et al (2012) Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8–10 prostate cancer. Int J Radiat Oncol Biol Phys 82:1949–1956

    Article  PubMed  Google Scholar 

  19. Fang LC, Merrick GS, Butler WM et al (2011) High-risk prostate cancer with Gleason score 8–10 and PSA level ≤ 15 ng/mL treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 81:992–996

    Article  PubMed  Google Scholar 

  20. Brenner DJ, Martinez AA, Edmundson GK et al (2002) Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52:6–13

    Article  PubMed  Google Scholar 

  21. Dearnaley DP, Sydes MR, Graham JD et al (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8:475–487

    Article  PubMed  Google Scholar 

  22. Stock RG, Cesaretti JA, Hall SJ et al (2009) Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU Int 104:1631–1636

    Article  PubMed  Google Scholar 

  23. Boladeras A, Santorsa L, Gutieerez C et al (2014) External beam radiotherapy plus single-fraction high dose rate brachytherapy in the treatment of locally advanced prostate cancer. Radiother Oncol 112:227–232

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no competing interests.

Compliance with ethical standards

All human and animal studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All persons gave their informed consent prior to their inclusion in the study.

Funding information

This study is not funded by any grant from any source.

Author information

Authors and Affiliations

  1. 21st Century Oncology Michigan, Healthcare Professionals, 28595 Orchard Lake Road, Farmington Hills, MI, 48334, USA

    Alvaro A. Martinez & Mihai Ghilezan

  2. Department of Radiation Oncology, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland, OH, USA

    Chirag Shah

  3. Radiation Oncology Consultants, Chicago, IL, USA

    Nasiruddin Mohammed

  4. Department of Radiation Oncology, University of California, Los Angeles, CA, USA

    D. Jeffrey Demanes

  5. Department of Radiation Oncology, Kiel University, Kiel, Germany

    Razvan Galalae

  6. Department of Radiation Oncology, University of Navarra, Pamplona, Spain

    Rafael Martinez-Monge

  7. Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USA

    Hong Ye

Authors
  1. Alvaro A. Martinez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chirag Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nasiruddin Mohammed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Jeffrey Demanes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Razvan Galalae
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rafael Martinez-Monge
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mihai Ghilezan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hong Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alvaro A. Martinez.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Martinez, A.A., Shah, C., Mohammed, N. et al. Ten-year outcomes for prostate cancer patients with Gleason 8 through 10 treated with external beam radiation and high-dose-rate brachytherapy boost in the PSA era. J Radiat Oncol 5, 87–93 (2016). https://doi.org/10.1007/s13566-015-0218-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13566-015-0218-3

Keywords

  • Prostate cancer
  • Brachytherapy
  • High risk
  • Radiation therapy